Effect of Peanut Consumption on Cardiovascular Risk Factors: A Randomized Clinical Trial and Meta-Analysis

dc.contributor.authorParilli Moser, Isabella
dc.contributor.authorHurtado Barroso, Sara
dc.contributor.authorGuasch-Ferré, Marta
dc.contributor.authorLamuela Raventós, Rosa Ma.
dc.date.accessioned2022-10-17T11:29:18Z
dc.date.available2022-10-17T11:29:18Z
dc.date.issued2022-04-01
dc.date.updated2022-10-17T11:29:18Z
dc.description.abstractAlthough numerous studies have reported the protective effect of nut consumption on cardiovascular risk, evidence for the role of peanuts in maintaining cardiometabolic health is inconclusive. Presented here are the results from the ARISTOTLE study, a parallel randomized controlled trial evaluating the impact of regular peanut intake on anthropometric, biochemical, and clinical measurements. The 63 healthy subjects that completed the study consumed their habitual diet plus either: a) 25 g/day of skin roasted peanuts (SRP, n = 21), b) two tablespoons (32 g)/day of peanut butter (PB, n = 23) or c) two tablespoons (32 g)/day of a control butter based on peanut oil (CB, n = 19) for 6 months. In addition, a meta-analysis of clinical trials, including data from the ARISTOTLE study, was carried out to update the evidence for the effects of consuming peanuts, including high-oleic peanuts, and peanut butter on healthy subjects and those at high cardiometabolic risk. After a systematic search on PubMed, Web of Science, Cochrane Library and Scopus databases up to July 2021, 11 studies were found to meet the eligibility criteria. In the ARISTOTLE study, lower total cholesterol/HDL-cholesterol and LDL-cholesterol/HDL-cholesterol ratios were found in the SRP group compared to the CB group (p = 0.019 and p = 0.008). The meta-analysis of clinical trials revealed that peanut consumption is associated with a decrease in triglycerides (MD: −0.13; 95% CI, −0.20 to −0.07; p < 0.0001) and that healthy consumers had lower total cholesterol and LDL-cholesterol/HDL-cholesterol ratios compared to the control groups (MD: −0.40; 95% CI, −0.71 to −0.09; p = 0.01 and MD: −0.19; 95% CI, −0.36 to −0.01; p = 0.03, respectively). However, individuals at high cardiometabolic risk experienced an increase in body weight after the peanut interventions (MD: 0.97; 95% CI, 0.54 to 1.41; p < 0.0001), although not in body fat or body mass index. According to the dose-response analyses, body weight increased slightly with higher doses of peanuts. In conclusion, a regular consumption of peanuts seems to modulate lipid metabolism, reducing triglyceride blood levels. Systematic Review Registration: https://osf.io/jx34y/, identifier: 10.17605/OSF.IO/MK35Y.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec724759
dc.identifier.issn2296-861X
dc.identifier.urihttps://hdl.handle.net/2445/189954
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3389/fnut.2022.853378
dc.relation.ispartofFrontiers In Nutrition, 2022, vol. 9, p. 853378
dc.relation.urihttps://doi.org/10.3389/fnut.2022.853378
dc.rightscc-by (c) Parilli-Moser, Isabella et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Nutrició, Ciències de l'Alimentació i Gastronomia)
dc.subject.classificationFruita seca
dc.subject.classificationPolifenols
dc.subject.classificationÀcids grassos saturats
dc.subject.otherDried fruit
dc.subject.otherPolyphenols
dc.subject.otherSaturated fatty acids
dc.titleEffect of Peanut Consumption on Cardiovascular Risk Factors: A Randomized Clinical Trial and Meta-Analysis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
724759.pdf
Mida:
2.31 MB
Format:
Adobe Portable Document Format